Researchers seek to tackle transplant tolerance using patients' own T cells

June 30, 2014

A new Northwestern Medicine clinical trial aims to remove the need for organ transplant patients to take immunosuppressive drugs by increasing the number of their own regulatory T cells (T-regs). The first-in-human, Phase I clinical trial, known as TRACT (T-regs for adoptive cell transfer), recently enrolled its first three participants in late May at Northwestern Memorial Hospital and was granted approval by the U.S. Food and Drug Administration (FDA) in March, 2014. Northwestern Memorial is the only enrollment site for this trial.

"T-regs play a critical role in creating transplantation tolerance and in controlling autoimmune diseases," said Joseph Leventhal, MD, PhD, director of kidney and pancreas transplantation for Northwestern Medicine's Comprehensive Transplant Center, professor of surgery at Northwestern University Feinberg School of Medicine and principal researcher for TRACT. "The core problem with autoimmune diseases is that their own immune system is actively attacking their body. In the case of transplant patients, their immune system views their new organ as a harmful intruder."

The therapeutic approach used by the TRACT clinical trial first isolates about 10 million T-regs from a participant prior to them receiving a . The isolated T-regs are then expanded in Northwestern Medicine's Matthews Center for Cellular Therapy until there are close to one billion individual cells, which are then given back to the participant through an intravenous infusion. While other studies using stem cells from living kidney donors have been successful in creating organ transplantation tolerance, which were also pioneered by Leventhal, TRACT's therapeutic approach to creating tolerance is equally applicable for deceased donor transplant recipients.

Currently, transplant recipients must take multiple toxic anti-rejection medications for the remainder of their lives so that the immune system is weakened to a point where it will no longer be able to effectively attack a transplanted organ. However, these drugs can cause serious side effects, including high blood pressure, diabetes, heart disease, cancer and an increased risk for infection. Anti-rejection medications even cause damage to organs like the liver and kidneys, which are often the same organs that are transplanted to save patients' lives. The new therapy used in Leventhal's TRACT study offers the potential for a better quality of life with fewer health risks for organ recipients.

In support of Leventhal's groundbreaking research, the Woman's Board of Northwestern Memorial Hospital recently provided a gift of $500,000 to help fund TRACT. The gift will enable the trial to be completed over the next calendar year and lay the foundation for the further development of TRACT's therapeutic approach as a Phase II trial.

"We are proud to be able to support this important and novel clinical trial," said Laura Davis, president of The Woman's Board. "Dr. Leventhal's research is very exciting and demonstrates a strong potential to drastically improve organ transplantation in the future."

"I am excited to be beginning this clinical trial and take the first steps toward what could be the next advancement in organ transplantation," said Anton I. Skaro MD, associate director of the Kidney Transplant Program for the Comprehensive Transplant Center, assistant professor of surgery at the Feinberg School of Medicine and principal investigator for TRACT. "While TRACT is currently focusing on removing the need for transplant patients to take anti-rejection medications, it also very exciting to note that this approach could prove useful for improving the lives of millions of individuals suffering from autoimmune disorders."

A total of 12 participants will be enrolled in the Phase I trial to test the safety of TRACT's therapeutic methodology. To qualify, participants must be 18 to 65 years of age, without a previous and require a single kidney organ transplant. Women participating in the study cannot be pregnant during the time of their transplantation and must use medically acceptable contraception throughout the clinical trial's treatment period.

Northwestern Medicine is celebrating the 50th anniversary of its first organ transplant in February, 1964. Today, Northwestern Medicine's Comprehensive Transplant Center is one of the largest and most successful organ transplant centers in the America, and is a leader in living donor liver and . Since 1964, Northwestern surgeons have performed more than 6,000 organ transplant surgeries and pioneered in transplantation research and technique. In order to make these critical services available to as many people as possible, Northwestern Medicine has opened satellite clinics in locations that include Peoria, Moline, Glenview and Joliet in Illinois, and Portage, Indiana. The Hispanic Transplant Program launched in 2006 making Northwestern the first institution in the country to have a specialized program dedicated to providing culturally sensitive care to the Hispanic population.

Explore further: New transplant method may allow kidney recipients to live life free of anti-rejection medication

Related Stories

New transplant method may allow kidney recipients to live life free of anti-rejection medication

March 7, 2012
New ongoing research published today in the journal Science Translational Medicine suggests organ transplant recipients may not require anti-rejection medication in the future thanks to the power of stem cells, which may ...

Optimizing donor kidney distribution in the United States

February 14, 2014
Northwestern University's Sanjay Mehrotra has developed an innovative model that could help ease kidney distribution inequities among regions in the U.S. and ultimately help save hundreds of lives. His mathematical model, ...

Antibody response linked with rejection in pediatric kidney transplant recipients

February 28, 2013
A transplanted kidney has a finite life expectancy because it often becomes the target of the recipient's immune system, which may mount antibodies that attack the organ. Because there is a critical need to extend the life ...

Kidney transplanted twice in two weeks

April 25, 2012
For the first time, a kidney that had been donated to a patient in need was removed and implanted into a new patient, the third individual to have the organ, after it failed in the first transplant recipient. Ray Fearing, ...

Researcher eyes kidney patient fracture risks

June 9, 2014
As if kidney disease wasn't bad enough on its own.

Recommended for you

Brain cells found to control aging

July 26, 2017
Scientists at Albert Einstein College of Medicine have found that stem cells in the brain's hypothalamus govern how fast aging occurs in the body. The finding, made in mice, could lead to new strategies for warding off age-related ...

Post-stroke patients reach terra firma with new exosuit technology

July 26, 2017
Upright walking on two legs is a defining trait in humans, enabling them to move very efficiently throughout their environment. This can all change in the blink of an eye when a stroke occurs. In about 80% of patients post-stroke, ...

Molecular hitchhiker on human protein signals tumors to self-destruct

July 24, 2017
Powerful molecules can hitch rides on a plentiful human protein and signal tumors to self-destruct, a team of Vanderbilt University engineers found.

Researchers develop new method to generate human antibodies

July 24, 2017
An international team of scientists has developed a method to rapidly produce specific human antibodies in the laboratory. The technique, which will be described in a paper to be published July 24 in The Journal of Experimental ...

New vaccine production could improve flu shot accuracy

July 24, 2017
A new way of producing the seasonal flu vaccine could speed up the process and provide better protection against infection.

A sodium surprise: Engineers find unexpected result during cardiac research

July 20, 2017
Irregular heartbeat—or arrhythmia—can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.